Rivastigmine for Alzheimer's disease-Reference-Cited by-同舟云学术

Rivastigmine for Alzheimer's disease

Published:2015-09-22 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Birks Jacqueline S¹,Chong Lee-Yee²,Grimley Evans John³

Affiliation:

1. University of Oxford; Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences; Botnar Research Centre, Windmill Road Oxford UK OX3 7LD

2. UK Cochrane Centre; Oxford UK

3. University of Oxford; Division of Clinical Geratology, Nuffield Department of Clinical Medicine; Radcliffe Infirmary Woodstock Road Oxford UK OX2 6HE

Publisher

Wiley

Subject

Pharmacology (medical)

Reference214 articles.

1. Efficacy and tolerability of rivastigmine in patients with dementia of the Alzheimer type;Agid;Current Therapeutic Research,1998

2. Efficacy and safety results of the early phase studies with Exelon (ENA-713) in Alzheimer's Disease: an overview;Anand;Journal of Drug Development and Clinical Practice,1996

3. Efficacy and safety results of the early phase studies with Exelon (ENA-713) in Alzheimer's Disease: an overview;Anand;Journal of Drug Development and Clinical Practice,1996

4. A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon®);Forette;European Journal of Neurology,1999

5. Effects of Alzheimer's disease severity on activities of daily living with long-term rivastigmine treatment;Anand;Journal of the American Geriatrics Society,2001

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design, Synthesis, and Biological Evaluation of Ferulic Acid-Piperazine Derivatives Targeting Pathological Hallmarks of Alzheimer’s Disease;ACS Chemical Neuroscience;2024-07-30

2. Synthesis and Biological Evaluation of Colchicine─Aryl/Alkyl Amine Hybrids as Potential Noncytotoxic Cholinesterase Inhibitors: Identification of SBN-284 as a Dual Inhibitor of Cholinesterases and NLRP3 Inflammasome;ACS Chemical Neuroscience;2024-07-26

3. Masitinib limits neuronal damage, as measured by serum neurofilament light chain concentration, in a model of neuroimmune-driven neurodegenerative disease;2024-03-12

4. Cholinesterase inhibitors-associated torsade de pointes/QT prolongation: a real-world pharmacovigilance study;Frontiers in Pharmacology;2024-01-11

5. Neuroprotective Profile of Triazole Grandisin Analogue against Amyloid-Beta Oligomer-Induced Cognitive Impairment;ACS Chemical Neuroscience;2023-12-04